REFERENCES
- Leppert W. The role of methadone in cancer pain treatment—a review. Int J Clin Pract. 2009;63:1095–1109.
- Manfreidi, PL, Borsook D, Chandler SW, Payne, R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain. 1997;70:99–101.
- Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin N Am. 2002;16:543–555.
- Shaiova L, Berger A, Blinderman CD, Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care. 2008;6:165–176.
- Weschules DJ, Bain KT. A systematic review of opioid conversation ratios used with methadone for the treatment of pain. Pain Med. 2008;9:595–612.
- Pollock AB, Tegeler ML, Morgan V, Baumrucker SJ. Morphine to methadone conversion: an interpretation of published data. Am J Hosp Palliat Care. 2011;28:135–140.
- Fine PG, Portenoy RK. Establishing ‘best practices’ for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418–425.
- Thomas Z, Bruera E. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage. 1995;10:315–317.
- American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 6th ed. Glenview, IL: American Pain Society; 2008:41–47.
- McPherson ML. Methadone: a complex and challenging analgesic, but it's worth it (Chapter 6, pp. 107–143) and patient controlled analgesia (Chapter 7, 145–166). In: McPherson ML, ed. Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. Bethesda, MD: American Society of Health-Systems Pharmacists; 2010.